您的位置： 美股首页 > Aerpio Pharmaceuticals Inc股票行情 > Aerpio Pharmaceuticals Inc公司档案
- 美东时间：8月23日 01：50：15
- 北京时间：8月23日 01：50：15
- 东京时间：8月23日 01：50：15
- 伦敦时间：8月23日 01：50：15
| 今开： | 涨跌： | 最高： | 市值(亿美元)： |
| 昨收： | 涨跌幅： | 最低： | 市盈率： |
Aerpio Pharmaceuticals Inc公司介绍
| 证券代码： | ARPO | 上市板： | - |
| 证券名称： | Aerpio Pharmaceuticals Inc | 上市场所： | 纳斯达克交易所 |
| 证券类型： | - | 发行方式： | - |
| 首发上市日： | 2018/06/26 | 首发价格(元)： | - |
| 首发数量(股)： | - | 首发募资总额(USD/元)： | - |
Aerpio Pharmaceuticals Inc基本资料
| 公司名称： | Aerpio Pharmaceuticals, Inc. | 注册地址： | 美国特拉华州 |
| 证券名称： | Aerpio Pharmaceuticals Inc | 上市场所： | 纳斯达克交易所 |
| 办公地址： | 9987 Carver Road, Cincinnati, Ohio, USA | ||
| 董事会主席： | - | 成立日期： | 2007/11/01 |
| 公司属地： | United States 美国 | 电话： | +1 (513) 985-1920 |
| 公司网址： | www.aerpio.com | ||
| 公司介绍： | Aerpio Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing first-in-class treatments for ocular disease. Its lead product candidate, AKB-9778, a small molecule activator of the Tie2 pathway, is being developed for the treatment of diabetic retinopathy, or DR, a disease characterized by progressive compromise of blood vessels in the back of the eye. The Tie2 receptor is expressed almost exclusively in endothelial cells (cells that make up blood vessels) and is essential for regulating vascular stability and preventing blood vessel compromise associated with diabetes. It have completed a Phase 2a trial of AKB-9778 in 144 patients with diabetic eye disease. Based on the results from this trial, it believe AKB-9778 has the potential to reverse the damage to blood vessels caused by diabetes. In contrast to marketed treatments for DR that are administered by a physician via intraocular injection, it intend to deliver AKB-9778 systemically by self-administered subcutaneous injection, similar to insulin. It believe that this delivery method provides an opportunity to treat diabetic eye disease at an earlier stage and reduces the likelihood of developing vision-threatening complications. |
||
